Valeant Pharmaceuticals International, Inc.’s (VRX) has price to cash ratio of 12.60. Further it is trading $-3.78 or -10.44% away its 200-day moving average of $36.22. Valeant Pharmaceuticals International has a 52-week low of $18.55 and a 52-week high of $245.82.
Advertisement
The Company has 345.47 million shares outstanding and 332.63 million shares were floated in market. Commonly named as P/E ratio, it helps investors know where the company stands in the market. Year-to-Date the stock performance stands at -69.67%. The company’s quarterly revenue was down 11.4% compared to the same quarter previous year. Earnings per share for the recently concluded quarter is expected to come in at $0.04/share with $506.14M in revenue.
Earnings growth is an important factor toresearch when buying stocks and investors look for stocks that have grown their earnings at least 25% or more for the past 3 years. The shares were acquired at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $30.9505. The disclosure for this purchase can be found here. This is an excellent indicator of heavy volume accumulation and distribution from institutional investors. Sapphire Star Partners LP raised its position in shares of Valeant Pharmaceuticals International by 100.0% in the first quarter.
Yesterday, VRX stock gained after the company announced that Paul Herendeen has taken over as the new CFO; he previously held the same position at Zoetis. Claren Road Asset Management Llc owns 77,527 shares or 18.46% of their United States portfolio. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares during the last quarter.
The amendment also allows the company to issue shorter-maturity secured notes and other debt in order to repay the term loans under the deal. Valeant Pharmaceuticals International, Inc.is in the Drug Delivery industry and Healthcare sector. 18 Analysts reported that the Price Target for Valeant Pharmaceuticals International, Inc. might touch $175 high while the Average Price Target and Low price Target is $44.39 and $16 respectively.
While looking at the Stock’s Performance, Valeant Pharmaceuticals International, Inc. now shows a Weekly Performance of 6.51%, where Monthly Performance is 32.35%, Quarterly performance is 15.4%, 6 Months performance is -61.45% and yearly performance percentage is -86.32%. Finally, Wells Fargo & Co. reissued a sell rating and set a $19.50 price target (down from $27.50) on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 7th.
Advertisement
A number of analysts rated the stock as well: 3 analysts believe that the stock is a STRONG BUY while 2 reported it as Buy.11 analysts assigned a HOLD rating, 3 said it’s UNDERPERFORM and 1 say that this stock is a SELL. The consensus price target lies at $38.59. The company exchanged total volume of 29.81 million shares throughout course of last trade however it holds an average trading capacity of 29.44 million shares. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
